Bristol Myers Squibb
American pharmaceutical company
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).
History
Squibb
The Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York after resigning from his assistant surgeon post from the U.S. Navy. The company started operating in a small brick laboratory in Brooklyn. It was reported that the nascent company almost closed upon its opening as the facility burned down on Christmas Eve of 1858. While the laboratory was destroyed, a group of doctors and surgeons helped Squibb reopen in 1859 by subscribing $2,100.
The public source identifies “Bristol Myers Squibb” as american pharmaceutical company. This brief keeps that definition visible, then builds a research path around Bristol, Myers and Squibb.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Bristol Myers Squibb”, the useful work is to connect “american pharmaceutical company” to the records capable of establishing context and consequence.
The record creator and administrative purpose are central evidence, because official documentation reflects both action and institutional priorities. The source revision retrieved here is dated Aug 25, 2026. The linked authority identifier is Q266423. VIAF identifies the subject as 144930641. The Library of Congress control number is nr90011300. 3 of 4 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 2025, 2000, 1858 and 1859.
Institutional narratives can privilege the records that survived while minimizing voices that were never formally collected. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Bristol Myers Squibb”, its source revision and the description used here.
- Expand the search: follow Bristol Myers Squibb primary sources, Bristol Myers Squibb archive and Bristol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Bristol Myers Squibb”?
- What chronology connects this entry to wider political or social change?
- Which voices are present, absent or mediated by the institution?
Search terms from this dossier
This entry incorporates text from “Bristol Myers Squibb” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.